Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
EMvision Medical DevicesASX:EMV -3.13%20 EV-to-EBITDA is -14.97 as of Jul. 28, 2026. GuruFocus rates ASX:EMV with a GF Score™ of 20/100. The stock has 3 warning signs investors should review. Among 510 Medical Devices & Instruments companies, EMvision Medical Devices ranks worse than 196078.24% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, EMvision Medical Devices's enterprise value is A$129.98 Mil.
EMvision Medical Devices's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-8.69 Mil. Therefore, EMvision Medical Devices's EV-to-EBITDA for today is -14.97.
The historical rank and industry rank for EMvision Medical Devices's EV-to-EBITDA or its related term are showing as below:
ASX:EMV'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.5 Med: 0 Max: 0
Current: -14.96
ASX:EMV's EV-to-EBITDA is ranked worse than 100% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.17
vs ASX:EMV: -14.96
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
EMvision Medical Devices (ASX:EMV) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EMvision Medical Devices's PE Ratio (TTM) for today is calculated as:
EMvision Medical Devices's share price for today is A$1.55.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. EMvision Medical Devices's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$-0.118.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, EMvision Medical Devices's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
EMvision Medical Devices EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, EMvision Medical Devices's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where EMvision Medical Devices's EV-to-EBITDA falls into.
EMvision Medical Devices's current Enterprise Value is A$129.98 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. EMvision Medical Devices's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was A$-8.69 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EMvision Medical Devices (ASX:EMV) has a EV-to-EBITDA of -14.97 as of Jul. 28, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on EMvision Medical Devices. According to the industry distribution chart, EMvision Medical Devices ranks #999999 out of 510 companies in the Medical Devices & Instruments industry.
Is EMvision Medical Devices' EV-to-EBITDA too high?
EMvision Medical Devices' current EV-to-EBITDA is -14.97. Based on the distribution chart, EMvision Medical Devices ranks #999999 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, EMvision Medical Devices has a GF Score™ of 20/100, reflecting its overall financial health beyond just this single metric.
How does EMvision Medical Devices' EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, EMvision Medical Devices ranks #999999 out of 510 companies for EV-to-EBITDA. This places EMvision Medical Devices in the lower half of its industry. The industry median EV-to-EBITDA is 14.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.17, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on EMvision Medical Devices. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. EMvision Medical Devices's current EV-to-EBITDA is -14.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is EMvision Medical Devices stock overvalued right now?
EMvision Medical Devices (ASX:EMV) has a current EV-to-EBITDA of -14.97. The current EV-to-EBITDA is -14.97. EMvision Medical Devices' overall GF Score™ is 20/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For EMvision Medical Devices (ASX:EMV), the current EV-to-EBITDA is -14.97 as of Jul. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
EMvision Medical Devices Ltd is an Australian medical device company. The company is focused on the research and development, and commercialisation of neurodiagnostic technology for stroke diagnosis and monitoring, as well as other medical imaging needs. Its focus is portable, cost-effective, and non-invasive brain scanners, including a bedside device (emu) and an ultra-lightweight pre-hospital device (First Responder). Its first indication targets acute stroke care, with a second planned indication in traumatic brain injury.
20GF Score
Get the complete analysis for ASX:EMV
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:EMV has been successfully added to your 
